BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
-13.72%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$2.5B
AUM Growth
+$2.5B
(-9.3%)
Cap. Flow
+$282M
Cap. Flow
% of AUM
11.27%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
89
New
6
Increased
32
Reduced
5
Closed
8
Top Buys
| 1 |
iTeos Therapeutics
ITOS
|
$45.1M |
| 2 |
Relay Therapeutics
RLAY
|
$41.9M |
| 3 |
Aclaris Therapeutics
ACRS
|
$39.3M |
| 4 |
argenx
ARGX
|
$31.5M |
| 5 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$30.4M |
Top Sells
| 1 |
AMRN
Amarin Corp
AMRN
|
$55.5M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$51.7M |
| 3 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$29.4M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
$6.95M |
| 5 |
Galapagos
GLPG
|
$6.83M |
Sector Composition
| 1 | Healthcare | 99.31% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GH Research
GHRS
$837M
| $170M | 6.79% | 9,275,158 | – | – |
|
2
Kymera Therapeutics
KYMR
$2.95B
| $152M | 6.07% | 3,586,658 +406,000 | +13% | +$17.2M |
|
|
3
Relay Therapeutics
RLAY
$619M
| $136M | 5.42% | 4,530,605 +1,400,000 | +45% | +$41.9M |
|
4
Arcus Biosciences
RCUS
$1.13B
| $125M | 5% | 3,960,948 +562,881 | +17% | +$17.8M |
|
5
Merus
MRUS
$4.98B
| $109M | 4.37% | 4,135,071 | – | – |
|
|
6
argenx
ARGX
$43.6B
| $99.7M | 3.99% | 316,204 +100,000 | +46% | +$31.5M |
|
7
Protagonist Therapeutics
PTGX
$3.67B
| $99.1M | 3.96% | 4,183,219 +531,460 | +15% | +$12.6M |
|
8
Xoma
XOMA
$392M
| $98.8M | 3.95% | 3,530,543 | – | – |
|
9
Repare Therapeutics
RPTX
$71.7M
| $83.4M | 3.34% | 5,858,776 +1,000,015 | +21% | +$14.2M |
|
|
10
Aclaris Therapeutics
ACRS
$209M
| $68.6M | 2.74% | 3,976,543 +2,280,639 | +134% | +$39.3M |
|
11
Crinetics Pharmaceuticals
CRNX
$2.92B
| $65.9M | 2.64% | 3,003,879 | – | – |
|
|
12
Galapagos
GLPG
$2.07B
| $64.9M | 2.6% | 1,046,283 -110,110 | -10% | -$6.83M |
|
13
Cullinan Oncology
CGEM
$445M
| $56.2M | 2.25% | 5,369,459 | – | – |
|
14
Kura Oncology
KURA
$686M
| $51.5M | 2.06% | 3,203,783 +1,139,571 | +55% | +$18.3M |
|
|
EQRX
15
DELISTED
EQRx, Inc. Common Stock
EQRX
| $49.7M | 1.99% | 12,025,570 +4,165,900 | +53% | +$17.2M |
|
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $48.9M | 1.95% | 1,597,966 -1,691,574 | -51% | -$51.7M |
|
17
Revolution Medicines
RVMD
$7.1B
| $46.2M | 1.85% | 1,810,549 | – | – |
|
|
18
iTeos Therapeutics
ITOS
| $45.1M | 1.8% | +1,400,201 | New | +$45.1M |
|
19
Relmada Therapeutics
RLMD
$37.2M
| $44.5M | 1.78% | 1,647,400 | – | – |
|
|
CTIC
20
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $41.7M | 1.67% | 8,929,690 | – | – |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $41.6M | 1.66% | 2,394,714 +295,000 | +14% | +$5.13M |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $40.3M | 1.61% | 2,664,521 +658,659 | +33% | +$9.96M |
|
23
Viridian Therapeutics
VRDN
$1.5B
| $32.2M | 1.29% | 1,744,012 -135,400 | -7% | -$2.5M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| $31.6M | 1.26% | 7,411,503 | – | – |
|
|
CINC
25
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $30.4M | 1.22% | +1,735,293 | New | +$30.4M |
|